The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group, as compared with the ipilimumab group.
what to use instead of azithromycin As a result, this medication helps lower the risk of heart related health events in people with risk factors for these issues.
